Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
64.00    2.00 (3.23%)
Bid:
63.00
Ask:
65.00
Spread: 2.00 (3.175%)
Market Cap: £15.59m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Progress Report on Trials and Cost Reduction

17 Aug 2015 07:00

RNS Number : 1851W
MyCelx Technologies Corporation
17 August 2015
 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Progress Report on Trials and Cost Reduction Initiatives

 

MYCELX Technologies Corporation (AIM: MYX), the clean water technology company providing patented solutions for commercial industrial markets worldwide, announces a progress report on trials in its key geographies and an update on cost cutting measures that are currently being implemented.

MYCELX is pleased to report progress in its three key geographies with regards to new installations and trials. The Company has recently completed its first installation for full water recycle and reuse for hydraulic fracturing in West Texas on a lease to purchase basis. Post successful trials, the system was installed to reduce operational costs through the production of high quality recycled water necessary for the fracturing process. In Saudi Arabia, MYCELX has commenced a trial with a SABIC affiliate to treat wastewater from a petrochemical maintenance operation which it believes will further bolster its prior successes in the turnaround market and accelerate project awards. As previously reported, the Company continues to progress applications of its technology in the Enhanced Oil Recovery segment of the market with a successfully completed third trial at a major producer's site in India.

The Company also reports that it has updated its cost reduction initiative and implemented additional expense control measures which include its Board of Directors and Key Management participating in a reduction in cash compensation until further notice. The impact of these efforts will be a reduction of the Company's cost base to below $9m for FY2016. These measures will enable the Company to be cash neutral from operations in H2 2015 and supports MYCELX's target to be operationally cash generative in 2016. The Company will continue to actively monitor costs in order to respond to changing market conditions. All cost reduction initiatives have been carefully targeted to preserve the Company's cash position whilst not impinging on MYCELX's ability to successfully convert its existing pipeline.

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO Tel: +1 888 306 6843

Mark Clark, CFO

 

RFC Ambrian Limited  Tel: +44 20 3440 6800

Corporate Finance

Samantha Harrison

Alexander Millar

 

Corporate Broking

Jonathan Williams

Kim Eckhof

 

Numis Securities Limited  Tel: +44 20 7260 1000

Corporate Broking

James Black

Ben Stoop

 

Bell Pottinger  Tel: +44 20 3772 2500

Nick Lambert

Henry Lerwill

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPKADNDBKBFFD
Date   Source Headline
3rd Jun 20267:00 amRNSAppointment of Non-Executive Director
12th May 20267:00 amRNSNew Gulf of Mexico Lease Award with Super Major
7th May 20267:00 amRNSFinal Results for the Year Ending 31 December 2025
16th Feb 202610:46 amRNSDirector Dealing
20th Jan 20267:00 amRNSTrading Update
22nd Dec 202511:27 amRNSHolding(s) in Company
7th Nov 20252:51 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSTrading Update & $3.9m Project Award
1st Oct 20257:00 amRNSHolding(s) in Company
23rd Sep 20255:00 pmRNSResult of Annual Meeting
23rd Sep 20257:00 amRNSAppointment of New Chairman and Succession
17th Sep 20257:00 amRNSHalf Year Results Statement
11th Sep 20257:00 amRNSClosure of Restricted Stock Line
22nd Aug 20257:00 amRNSMailing of Notice of 2025 Annual Meeting
20th Aug 20257:00 amRNSOpening of $500,000 Line of Credit
17th Jul 20257:00 amRNSTrading Update
10th Jun 20257:00 amRNSMailing of 2024 Annual Report
21st May 20253:25 pmRNSDirector Dealing
19th May 202511:33 amRNSHolding(s) in Company
15th May 202511:21 amRNSHolding(s) in Company
12th May 20257:00 amRNSFinal Results for the Year Ending 31 December 2024
6th May 20257:00 amRNSPFAS Contract Award
1st May 20257:00 amRNS-REPA Announces Actions to Combat PFAS Contamination
10th Apr 20257:00 amRNSGrant of Share Options
7th Apr 20257:00 amRNSOperational and Trading Update
30th Jan 20257:00 amRNSChange of Adviser
6th Jan 20257:00 amRNSYear-end Update
29th Oct 20247:00 amRNSProject Award
24th Sep 20247:00 amRNSHalf Year Results Statement
23rd Sep 20247:00 amRNSTrading Update
6th Sep 202411:54 amRNSHolding(s) in Company
5th Sep 20245:17 pmRNSHolding(s) in Company
30th Aug 20247:00 amRNSBroker Option
23rd Aug 202411:05 amRNSDirector Dealings & Total Voting Rights
23rd Aug 20247:00 amRNSProposed Placing and Subscription
19th Jul 202410:36 amRNSPFAS Update
9th Jul 20242:23 pmRNSResult of AGM
9th Jul 20241:39 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNS2023 Annual Report & Notice of 2024 Annual Meeting
21st May 20247:00 amRNSDirector Dealing
16th May 20247:00 amRNSFinal Results for the Year Ending 31 December 2023
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.